How Falling Sequencing Costs and Integrated Workflows Are Shaping Genomics

The sub-$100 genome is here, and the cost floor keeps dropping. Ultima at $80, Element at $100, Roche at $150—and I'm not sure where this stops. As sequencing cost compresses, the bottleneck is shifting to everything around it—upstream sample handling and preparation, and downstream data interpretation and bioinformatics. 

The push toward integrated solutions and the tension it creates. The industry is moving toward end-to-end workflows—sequencing companies building out clinical pipelines with built-in interpretation, connecting sample-to-answer systems, and actively seeking partners to fill workflow gaps rather than building everything in-house.

Genomics is moving into clinical and industrial applications at scale. The presence of hospitals and medical centers at AGBT this year was noticeably stronger. Keynotes showcased clinical genetics workflow data, and more broadly, sequencing company revenues are trending up in the clinical space.

The conversation has shifted from 'can we sequence?' to 'can we operationalize sequencing in a clinical and industrial setting?' That means automation to address labor shortages, reproducibility for diagnostic-grade quality, and validated workflows that don't require months of method development.

The labs processing thousands of patient genomes today are the ones that solved the operational problem, not just the science problem.

AGBT made it clear that PCR-free whole-genome sequencing (WGS) is moving into clinical adoption, driven by falling costs from next-generation short-read platforms (Ultima, Element, Roche, Illumina). As cost approaches ~$100/genome, WGS at scale is becoming practical.

At the same time, accuracy is rising alongside throughput, with approaches like ppmSeq and emerging ultra-high-quality reads enabling more sensitive applications. This puts increasing emphasis on the underlying library prep and amplification chemistry to fully realize these gains.

There is also growing interest in new approaches that extend the capabilities of short-read sequencing, including methods that capture additional genomic context and structure, alongside continued momentum in multiomics, particularly direct methylation detection (e.g., TAPS+).

Across these trends, the common theme is clear: more information from the same sample, without added workflow complexity.

The Callisto Complete Kit for DNA EF Library Prep represents an important step toward fully integrated sequencing workflows. By combining Watchmaker Genomics’ high-quality reagents with a ready-to-run workflow on Callisto, we’re simplifying what has traditionally been a fragmented and complex process.

One of the key challenges in sequencing today isn’t just throughput—it’s operational complexity. Labs often have to manage and track multiple stock-keeping units (SKUs), vendors, and protocol variations for a single workflow. With the Callisto Complete Kit, we move toward a one-SKU solution, reducing that burden and making it easier for labs to deploy and scale without worrying about coordinating multiple components.

At the same time, this integration helps address the variability and manual complexity that have made library prep a bottleneck. By standardizing the workflow on Callisto, the kit enables more consistent execution and reproducible results.

From a performance standpoint, it delivers highly consistent fragment size distributions and low duplication rates (<10%), maximizing usable sequencing reads—even for demanding applications like WGS.

Overall, this solution is a first step toward our broader vision of delivering complete, integrated workflows that simplify operations while enabling labs to scale with confidence.

PCR-free workflows offer clear advantages in reducing bias and improving data quality, but they come with a few practical challenges for labs.

First, they typically require higher DNA input and very precise handling, since there’s no amplification step to compensate for losses. That makes workflows more sensitive to variability. Second, they can be more difficult to scale, as maintaining consistency across samples without PCR requires tight process control. And finally, manual workflows increase the risk of variability and sample loss, which can impact library yield and sequencing performance.

Callisto addresses these challenges by automating the entire library prep workflow, ensuring consistent handling across samples and minimizing variability. Standardizing key steps like fragmentation, cleanup, and size selection, helps labs achieve reliable yields and reproducible results, even in PCR-free workflows.

Ultimately, it enables labs to realize the benefits of PCR-free prep—lower bias and higher data quality—without sacrificing scalability or consistency.

Callisto was designed for any lab where sequencing matters, but complexity gets in the way—and that's a much broader universe than people assume.

What we're seeing from early adopters tells that story clearly. In clinical settings—hospital labs running newborn screening programs, using WGS as the backbone for those tests—we're seeing greater than 95% success rates with real patient samples. That's not a controlled research environment. That's a high-stakes clinical workflow, and that level of reliability changes what's possible for those labs.

The second thing we're hearing is equally powerful: Callisto is removing the barrier to adopting entirely new sequencing methods. We have labs that have built their operations around short-read sequencing and want to bring long-read technologies online to complement what they do—but historically, that meant months of method development, validation, and training. With Callisto, they buy a kit and get going. The expertise is already built in.

That's what we mean when we talk about deploying capability. It's not just about making existing workflows faster—it's about giving labs the confidence to expand what they offer without expanding their overhead. That's the shift Callisto is enabling.

The next three to five years in sequencing aren't just about faster or cheaper reads—they're about who gets to sequence.

We're moving from a world where high-quality genomic data lives in core facilities to one where it's generated everywhere: in community hospital labs, regional diagnostic centers, smaller biotech teams, and even field research settings that never had access before. That transition depends entirely on what happens upstream. Library prep has to become faster, more automated, and reproducible regardless of who's running it.

When you remove the complexity from prep, you change who can participate in genomics. That's not an incremental improvement—that's a category shift. At Volta, that's exactly what we're building toward.

Sequencing will be defined by the convergence of throughput, accuracy, and workflow innovation. High-quality data generation from library prep through sequencing will be critical to enabling applications like multi-cancer early detection and minimal residual disease.

We expect increasing integration of genetic, epigenetic, and positional signals in a single workflow, alongside continued growth of long-read approaches and population-scale WGS.

As data scales, AI-driven analysis will accelerate interpretation, but ultimately, better insights will depend on robust, scalable chemistries that preserve signal from challenging samples and enable consistent performance across workflows.

The introduction to this interview includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.